From: PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Study | Histology | Treatment | # patients | ORR (%) | Median response duration (months) | OS (months) |
---|---|---|---|---|---|---|
Nivolumab | ||||||
 Gettinger et al. [11]a | All | Nivolumab 3 mg/kg q2wks | 37 | 24.3 | 17 | 14.9 |
Nivolumab 10Â mg/kg q2wks | 59 | 20.3 | 19.1 | 9.2 | ||
 Rizvi et al. [13] (CHECKMATE 063) | Squamous | Nivolumab 3 mg/kg q2wks | 117 | 14.5 | Not reached | 8.2 |
 Brahmer et al. [14] (CHECKMATE 017) | Squamous | Nivolumab 3 mg/kg q2wks | 135 | 20 | Not reached | 9.2 |
Docetaxel 75Â mg/m2 q3wks | 137 | 9 | 8.4 | 6 | ||
 Borghaei et al. [15] (CHECKMATE 057) | Non-squamous | Nivolumab 3 mg/kg q2wks | 292 | 19 | 17.2 | 12.2 |
Docetaxel 75Â mg/m2 q3wks | 290 | 12 | 5.6 | 9.4 | ||
 Bauer et al. [55] | All | Nivolumab 3 mg/kg q 2wks | 51 | 13.7 | Not reported | Not reported |
Pembrolizumab | ||||||
 Garon et al. [16] (KEYNOTE 001) | All | Pembrolizumab 2 mg/kg q3wks | 6 | 33.3 | 12.5 | 9.3 (prior therapy) |
Pembrolizumab 10Â mg/kg q3wks | 287 | 19.2 | ||||
16.2 (no prior therapy) | ||||||
Pembrolizumab 10Â mg/kg q2wks | 202 | 19.3 | ||||
 Herbst et al. [17] (KEYNOTE 010) | All | Pembrolizumab 2 mg/kg q3wks | 344 | 18 | Not reached | 10.4 |
Pembrolizumab 10Â mg/kg q3wks | 346 | 18.5 | Not reached | 12.7 | ||
Docetaxel 75Â mg/m2 q3wks | 343 | 9.3 | 6 | 8.5 |